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Over the last half-century, understanding the manifestations and molecular pathogenesis of Gaucher 
disease has captured the attention of investigators and physicians. Persistent investment in this 
research has led, among other discoveries, to a portfolio of effective treatments for several 
lysosomal disorders.  As an exemplary physician-investigator, Dr. Roscoe Owen Brady (1923-2016) 
was for a long period, the driving force behind many of these accomplishments. He set high 
standards for discovery based on the use of innovative research tools (including the synthesis of 
pure, radiolabeled natural lipid substrates) in the investigation and treatment of 
glycosphingolipidoses. Brady’s fiercely rational approach and sheer stamina in tackling phenotypically 
and biochemically complex disorders is an inspiration for present-day researchers and clinicians. 
Indeed, as an example of scientific courage, his prodigious achievements and interdisciplinary 
research conducted over more than sixty years, warrant special commemoration since they are 
instructive for those who choose roads that are far away from the beaten track. Once established, 
Roscoe Brady spent his entire career as Chief of the Developmental and Metabolic neurology branch 
of the National Institute of Neurological Disorders and Stroke at the National Institutes of Health, 
Bethesda. At the Institute, Brady made seminal contributions to the understanding of 
glycosphingolipidoses, including the Niemann-Pick diseases, Fabry disease and Tay-Sachs disease. 
Here we focus principally on his prodigious and perhaps best-known accomplishments in Gaucher 
disease. 
After obtaining his M.D. at Harvard Medical School in 1947 and completing his internship at the 
University of Pennsylvania, while remaining attached to the department of Medicine, Roscoe Brady   
took up a research fellowship award to study the biochemistry of lipids. In the group of Dr Samuel 
Gurin at the University, he collaborated with others to elucidate the synthesis of long chain fatty 
acids and in this environment of ‘basic’ science, became acquainted with advanced techniques in 
lipid research [1]. The laborious but productive training in lipid biochemistry left its mark and 
prepared Brady for his own programme of research into lipid chemistry in the Neurochemistry 
Laboratory at the Neurology Branch of the National Institutes of Health in Bethesda, Maryland (then 
quaintly known as the National Institute of Neurological Diseases and Blindness), which he joined in 
the late 1950s after two years of active clinical service in the United States Navy. After appointment 
as Assistant Chief in Neurochemistry, Brady investigated the enzymatic synthesis of sphingosine and 
developed an interest in sphingolipids [2, 3]. Almost inevitably, Gaucher’s disease was among his 
main research interests.  In January 1882, the young physician P.C.E. (Ernest) Gaucher described in 
his doctorate at the University of Paris, entitled: ‘De l'epithelioma primitif de la rate, hypertrophie 
idiopathique de la rate sans leucemie’, the findings at a postmortem personally conducted at the 
Hôpital Cochin, on a cachectic (31 Kg) woman of 34 years with a bleeding tendency and ill-health 
since the age of seven, who had died under his care.   The spleen and liver were grossly enlarged 
(3.88 Kg and 4.77 Kg, respectively); but examination using the best technology of the day (optical 
microscopy), revealed spectacular findings in the sinusoids of the spleen which contained abnormal 
cellular infiltrates (tissue macrophages) [4]. These cells are beautifully depicted in camera lucida 
drawings of splenic tissue sections by Gaucher himself. Within a few decades it was realized that this 
patient had suffered from a distinct inheritable disease entity that was subsequently named 
Gaucher’s disease (GD). In 1924, Emil Epstein isolated a pathological substance from the spleen of a 
similar patient; this material was soluble in alcohol but insoluble in acetone [5]. In the same year, 
analysis by the Austrian chemist, Hans Lieb, led to the discovery of gross accumulation of a 
glycosphingolipid - a cerebroside, as originally designated by Johannes Thudichum [6, 7]. In his paper 
Cerebroside Speicherung bei Splenomegalie Typus Gaucher, Lieb erroneously assumed that the 
storage material was galactosylceramide, a glycosphingolipid whose metabolism was much later 
shown to be disturbed in the inherited disorder Krabbe disease  (caused by deficiency of the acid β-
galactosidase named galactocerebrosidase) [5, 7].  
The correct structure of the storage lipid in Gaucher disease as ß-glucosylceramide 
(glucocerebroside; GlcCer), was reported in spleen tissue obtained from a severely affected young 
girl, who died at the age of nine years with a neurological variant of Gaucher disease and massive 
visceromegaly and other features; the patient had been treated by splenectomy. This was 
documented by another French physician, Henriette Aghion, of l’Hôpital Rothschild: she had secured 
the expertise of a pharmacy intern, M. Lardé, based at a neighbouring institution (L’Hôpital 
Trousseau). In her doctoral dissertation in Medicine, like that of Ernest Gaucher also awarded by the 
University of Paris, entitled ‘La Maladie de Gaucher dans l'Enfance (forme cardio-rénale)’, Aghion 
noted the unequivocal identification of glucose by her collaborator [9]. The pathological 
glucocerebroside was confirmed (by the reducing properties, melting point and ozazone) of the 
cognate hexose liberated by hydrolysis of the purified material after prolonged treatment with acid-
methanol. The definitive confirmation of glucosylceramide as the pathological storage lipid was 
presented by the work of Rosenberg and Chargaff in 1958 [10]. 
Of crucial importance at the outset of his investigations into Gaucher disease, Roscoe Brady 
formulated a clear research question: ‘what is the basic cause of the glucocerebroside accumulation?’ 
He examined this problem in a highly systematic manner –  the hallmark of his scientific approach. 
Keenly employing state-of-the-art techniques using radioactive lipid precursors synthesized in 
collaboration with expert chemists, David Shapiro and Julian Kanfer, together with Eberhard Trams, 
examined capacity for de novo formation of glucocerebroside by splenic tissue. In contrast to what 
had been assumed earlier, the biosynthesis was not impaired [11]. Subsequently, in a series of 
investigations he provided compelling evidence for defective breakdown of GlcCer in GD. The activity 
of an acid β-glucosidase named glucocerebrosidase was shown to be markedly reduced in 
homogenates of spleen and other tissues obtained from Gaucher patients [12-14]. Independently, Dr 
Desmond Patrick at the Institute of Child Health (University College London) at Great Ormond Street 
Hospital, London using an artificial β-glucosidic substrate, the deficiency of acid β-glucosidase activity 
was also shown in [15]. Ernest Beutler developed soon afterwards a more sensitive and facile 
enzymatic assay for diagnostic purposes based on a fluorogenic artificial substrate [16].  A few years 
before, Christian de Duve and colleagues had identified lysosomes as sub-cellular acidic 
compartments involved in macromolecular degradation that harbour a portfolio of specific enzymes 
with acid pH optima for this purpose. The presence of a glucosylceramide-degrading acid β-
glucosidase and other acid hydrolases with activity against sphingolipid substrates in lysosomes was 
first reported in 1968 by Dr Neil Weinreb, then working in the Brady laboratory at the National 
Institutes of Health [17]. These findings demonstrated the central rôle of the lysosome in the 
breakdown and recycling of cellular sphingolipids implicated in several important diseases, including 
Niemann-Pick diseases A and B and Fabry disease. 
Identification of the primary defective protein, lysosomal acid β-glucosidase, in Gaucher disease, 
initiated another phase of endeavour: the investigation of enzymes. Here again Brady formulated 
another crucial and rational question: ‘what is the nature of glucocerebrosidase and how is it 
impaired in Gaucher disease?’ This question was particularly relevant on account of the appreciable 
residual activity that was obtained with assays employing natural substrates [13, 14].  Purification 
and characterization of glucocerebrosidase presented many difficulties:  the relative low abundance 
of the protein; its tendency to adhere to membranes and other hydrophobic proteins as well its 
intrinsic heterogeneity due to variably sialylated N-linked glycans. With formidable persistence, 
assisted by Peter Penchev, Scott Furbish and others, the enzyme was ultimately purified to 
homogeneity from human placenta. Later, the entire 495 amino acid sequence was meticulously 
determined by sequencing based on the Edman-degradation method; in addition, the glycan 
composition was determined by mass spectrometry. These were truly heroic achievements at that 
time [18-20]. Again, this fundamental work provided a solid basis for improved diagnosis of Gaucher 
disease and characterization of the mutant enzyme in patients employing specific antibodies [21]. 
Moreover, the detailed knowledge which had been gained about the enzyme greatly facilitated 
subsequent applications in the direction of therapeutic administration of enzyme and gene transfer – 
in short, a clear pathway of translational research.  
Having identified and characterized the culprit enzyme in Gaucher disease, Roscoe Brady formulated 
another essential research question: ‘can exogenous glucocerebrosidase correct the defect?’. The 
target cell for correction was defined by him as the tissue macrophage, the primary pathological 
storage cell first identified by Ernest Gaucher. In a series of systematic investigations, the importance 
of glycan composition of glucocerebrosidase for its delivery to lysosomes of macrophages was 
identified [22]. Critically, Roscoe Brady and his colleagues exploited the newly recognized receptor-
mediated endocytosis of proteins to lysosomes and the unique presence of mannose-receptors on 
macrophages [22]. This allowed him and by now the multidisciplinary research team he assembled, 
including clinicians, molecular biologists and biochemists such as John Barranger, Norman Barton, 
Edwards Ginns and Gary Murray, to design an appropriate enzyme with mannose-terminated 
glycans. The initial reports of the Brady team on clinical responses to human placental 
glucocerebrosidase with glycan modification to expose terminal mannose ligands manufactured in 
collaboration with Genzyme were seminal in the therapeutic realization of this extraordinary 
programme of research [23, 24]. The clinical success of this rational stratagem for treatment, often 
termed enzyme replacement therapy, is well documented: rightly, Roscoe Brady’s achievements 
were acknowledged by the Lasker Foundation Clinical Medical Research Award, the National Medal 
of Technology and Innovation and the Kovalenko Medal from the National Academy of Sciences. The 
astonishing success of enzyme therapy in reversing, as well as preventing the principal visceral and 
haematological manifestations of Gaucher disease in children and adults, was not only life-changing 
for patients all over the world but also transformed the entire field of research into lysosomal 
disorders. From the outset, even with the placenta-derived human tissue enzyme, not only did the 
success of therapy revive the interest of investigators and clinicians in these disorders, but it boosted 
the biopharmaceutical development of recombinant glucocerebrosidase preparations produced on 
different expression platforms and by several competing companies. Later, by then able to take 
advantage of opportunities offered by Orphan Drug legislation in many countries, the commercial 
success of enzyme therapy in Gaucher disease greatly incentivized the introduction of other 
genetically engineered recombinant lysosomal hydrolases for treating corresponding lysosomal 
disorders.  
Enzyme therapy is effective in correcting the pathological phenotype of tissue macrophages present 
in the viscera and the attendant clinical complications of Gaucher disease. However, it is unable to 
address the manifestations of established disease associated with fibrotic scarring and inflammation 
in for example the skeleton; and clearly parenteral enzyme cannot prevent neurological 
manifestations characteristic of patients with the more severe forms of disease. Roscoe Brady also 
took up this latter formidable challenge and together with Dr Raphael Schiffmann (presently Baylor 
Research Institute, Dallas), also investigated the efficacy of administration of enzyme to the brain 
[25-27]. In parallel, he fostered the work on gene therapy by his fellow Stefan Karlsson who 
subsequently also generated now widely used mouse models of Gaucher disease [28, 29]. Gene 
therapy research was sustained successfully by Jeff Medin (presently University of Toronto); latterly, 
Stefan Karlsson (presently at Lund University) has generated third-generation advanced lentiviral 
vectors with the promise of human application [30]. Future success of gene therapy of 
neuronopathic Gaucher disease soon may also be attributable to Brady’s fundamental contributions - 
including the joint work with Mia Horowitz, Ari Zimran and others on the characteristics of the 
glucocerebrosidase gene and its pathological mutations (GBA1, locus 1q21) [31]. Late in life, Roscoe 
Brady remained eager to stimulate definitive and well thought-out alternative investigation of 
treatments for Gaucher disease; and his deep knowledge of sphingolipid biochemistry, enzymology 
and molecular biology facilitated exploration of molecular chaperone therapy as well as potential 
therapeutic use of HDAC inhibitors [32-34]. Over the years, he promoted the work of innumerable 
acolytes and talented young research scientists worldwide – often providing invaluable guidance for 
the clear formulation and realization of their ideas.  
In a brief autobiographical article, Roscoe Brady revealed that as a third-year clinical medical student 
at Harvard during the dark days of World War II, two encounters with young patients who suffered 
fatal complications of heart disease moved him to seek a life-long scientific path in lipid research 
[35]. Rather than pursue a specialist career in what would have been ‘patch-up’ medicine or cardiac 
surgery, and at a time when practically nothing was known about the metabolism of fatty acids or 
cholesterol, he planned his unconventional career departure. Immediately after completing his 
internship at the University hospital of Pennsylvania, Brady applied for and was awarded a National 
Research Council fellowship in the Department of Biochemistry at the University of Pennsylvania 
School of Medicine. 
During his entire career, Brady was intrigued by the potential toxicity of lipid metabolites – this 
fascination was later extended to the glycosphingolipidoses as the portfolio of opportunities opened 
up at the Neurochemistry laboratory in the National Institutes of Health and as his biochemical skills 
and confidence expanded.  In general, research interests in metabolites, a popular research topic up 
to the nineteen sixties, waned:  the characterization of proteins, logically followed by genetics, as the 
science of molecular biology became accessible to experiment, soon claimed centre stage in 
biomedical research. During a long and highly productive working life, Roscoe Brady witnessed these 
transitions - and it is notable that he seemed easily to negotiate the conceptual and the technical 
inventiveness that innovation demanded. Indeed, he had a striking capacity to integrate 
methodological advances and bring new platforms of discovery to bear on the research being 
undertaken in his laboratory.  
When first in the laboratory, Brady carried out demanding studies on the biochemistry of fatty acid 
biosynthesis: he used his empirical knowledge gained from the study of enzyme-catalyzed acetyl 
transthiolation reactions, to discover the critical involvement of malonyl-CoA in the biosynthesis of 
long-chain fatty acids - ultimately identifying the mechanism of the condensation reaction 
responsible [36-38]. This work, initiated again during hard times (of the Korean war, 1952-4), and 
during secondment as head of the clinical chemistry laboratory at the National Naval Medical Center 
in Bethesda, was completed after his precocious appointment to the combined basic research 
laboratories of the then National Institute of Neurological Diseases and Blindness and the National 
Institute of Mental Health. From this time, in an environment enriched by neuroscience and 
enthusiastic chemists, Roscoe Brady’s research interests naturally moved to the metabolism of lipid 
molecules of importance in nervous tissue. In work of prescient significance, he embarked on 
investigations into the biosynthesis of the principal lipid of the brain, the sphingolipid, 
galactocerebroside (galactosylceramide). Sphingolipids are defined by a unique component, 
sphingosine - a long-chain amino alcohol with enigmatic properties so named by its discoverer, JLW 
Thudichum. Cerebrosides, of which glucosylceramide that is found in excess in Gaucher disease is a 
class member, contain long-chain fatty acids and sugar moieties linked to the sphingosine moiety. 
After defining the requirements for formation of sphingosine de novo from palmitoyl CoA and L-
serine [39], Brady and colleagues set out systematically to explore biosynthesis of cerebrosides:  in 
brain microsomes, incorporation of glucose and galactose was found to depend on the presence of 
energy-rich nucleotide sugars, which had been identified in the contemporaneous (and ultimately 
Nobel prize-winning) discoveries of Luis Leloir [40]. These investigations, involving UDP-glucose and 
UDP-galactose as hexose donors - combined with Brady’s deep knowledge of the demanding 
methodology - immediately made possible exploration of the key biosynthetic reactions leading to 
formation of all three component moieties of the cerebrosides. In a synergistic collaboration with 
David Shapiro from The Weizmann Institute of Science, Brady was able to develop sophisticated 
radio-labelled substrates suitable for investigating the fundamental defect in Gaucher disease. Later 
he studied the metabolism of more complex sphingolipids, including the globosides and gangliosides 
implicated in related disorders of iconic pathological obscurity; with this, the stage was set for 
discoveries in what grew exponentially generate an important and competitive field of enzymology. 
While Okada and O’Brien were the first to discover the enzyme defect in hexosaminidase A 
responsible for Tay-Sachs disease, Brady’s laboratory rose rapidly to a dominant position. This was 
further evident from studies of sphingomyelin metabolism implicated in classical Niemann-Pick 
disease and the identification of alpha-galactosidase deficiency responsible for Anderson-Fabry 
disease.  
As shown above, profound methodological understanding and a systematic but interdisciplinary 
approach to biological research proved critical for a succession of discoveries in the whole field of 
sphingolipid biochemistry by the Brady Laboratory at NIH. These were translated into studies of 
molecular pathogenesis, diagnostic enzymology and genetics - as well as applied therapeutic science. 
A striking outcome of the work programme reflects two contrasting but clinically validated means of 
treating glycosphingolipid diseases: targeted molecular therapy involving replacement of the missing 
factor (usually a matrix enzyme) or the use of specific inhibitory molecules to rebalance the rate of 
glycosphingolipid biosynthesis with its rate of breakdown. This latter stratagem, so-called substrate-
reduction therapy, later taken up by Norman Radin, Frances Platt and James Shayman and their 
associates.  It is notable that Brady’s early excursions into the sphingolipid field involved studies of 
Gaucher disease: eventually it was the prodigious efforts of his laboratory in this disease that yielded 
his most productive and worthwhile discoveries as applied to medicine. These achievements were 
not only recognized by his early election as a Member of the National Academy of Sciences and 
award of a Lasker prize and other prestigious awards, but they gave Roscoe Brady a deep personal 
satisfaction. This depth of feeling is no more evident than in images in which he is shown in the 
company of patients whose lives were dramatically changed by his enduring commitment to clinical 
research [35].  
Although Roscoe Brady remained faithful to his first love of lipid biochemistry, his lifetime of 
scientific work retained a strong translational perspective; and throughout, his underlying motivation 
to improve clinical practice and develop credible therapies was undimmed. At times he could appear 
brusque with those who had a superficial scientific understanding, but his adherence to invariant 
biological principles was unerring and his behaviour in the presence of distressed patients was 
dignified and caring. From the scientific aspect, Roscoe Brady’s advice carefully to re-examine 
metabolite abnormalities in glycosphingolipidoses using advanced mass spectrometric techniques 
should be taken to heart. Indeed, in Gaucher disease it is not only glucosylceramide that 
accumulates, but also the unacylated sphingolipid, glucosylsphingosine – concentrations of which are 
elevated several hundred-fold in body fluids and tissues. That the same phenomenon also holds true 
for Fabry disease where, in addition to the excessive globotriaosylceramide, the water-soluble base, 
globotriaosylsphingosine is prominently increased, was a consequential finding that delighted Dr 
Brady [41]. There is mounting evidence that that the minor glycosphingoid base abnormalities in 
several of the sphingolipidoses disease contribute to tissue injury and other manifestations: the 
pathological overproduction of glucosylsphingosine has been linked to B-cell lymphoma [42, 43] and 
it has been recently reported that Gaucher-related glycolipids act as auto-antigens driving B-cell 
proliferation - thus directly promoting development of multiple myeloma, a blood cell cancer 
occurring with a greatly increased frequency in patients with Gaucher disease [44]. Excessive 
galactosylsphingosine is widely regarded as toxic to oligodendroglia and their precursors in Krabbe 
disease [45] and excessive globotriasylsphingosine has been reported to be toxic for nociceptive 
peripheral neurons and podocytes in Fabry disease patients [46, 47]. Dr Brady’s admonitions to 
explore fundamental aspects of disease may also be justified in terms of physiological understanding, 
since deacylation of complex sphingolipids to water-soluble derivatives may represent a natural 
means for their transport and ultimate disposal. 
Envoi 
In a long and creative life of discovery and one populated by gifted colleagues and high achievement, 
Dr Brady’s reputation should move honorably to that offered by posterity. Here it places on us a duty 
to crystallize his legacy in context. In this great man, we have a person whose skill and staying power 
marks him out on account of his revolutionary introduction of an effective molecular therapy for a 
diverse and challenging lysosomal disease – thus far beyond expectations realizing Christian de 
Duve’s original prediction. The therapeutic achievement alone, with all the attendant economy of 
orphan medicinal drugs, is a legacy of immense human and tangible value. We also have in Dr Roscoe 
Brady a gifted physician-scientist educated in the teutonic tradition of biochemistry, who sublimated 
his sympathetic feelings and engaged prodigious innate abilities to attain the highest level of 
scientific attainment, the better to discover and unravel the complexities of human disease. There 
was much that was private and discreet in Dr Brady and he rarely gave away his true feelings; but 
large numbers of colleagues and associates as well as patients and industrial collaborators held him 
in thrall. For his contributions to medicine and to science, brought about by his intellectual 
leadership and capacity to share; for his imagination as an investigator, as well as sheer doggedness, 
he commands our deepest and enduring respect.  
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